基于人工智能进化和抗原性模型的流感疫苗株选择

IF 50 1区 医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY
Wenxian Shi, Jeremy Wohlwend, Menghua Wu, Regina Barzilay
{"title":"基于人工智能进化和抗原性模型的流感疫苗株选择","authors":"Wenxian Shi, Jeremy Wohlwend, Menghua Wu, Regina Barzilay","doi":"10.1038/s41591-025-03917-y","DOIUrl":null,"url":null,"abstract":"<p>Current vaccines provide limited protection against rapidly evolving viruses. For example, Centers for Disease Control and Prevention estimates show that the overall influenza vaccine effectiveness against outpatient illness in the United States averaged below 40% between 2012 and 2021. Moreover, the clinical outcomes of a vaccine can be assessed only retrospectively. Here we propose an in silico method named VaxSeer that predicts the antigenic match of vaccine candidates with circulating viruses, in the context of the viruses’ relative dominance in the future influenza season. Based on 10 years of retrospective evaluation using sequencing and antigenicity data, our approach consistently selects strains with better empirical antigenic matches to circulating viruses than annual recommendations. Finally, our predicted estimate of antigenic match exhibits a strong correlation with influenza vaccine effectiveness and reduction in disease burden, highlighting the promise of this framework to drive the vaccine selection process.</p>","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"10 1","pages":""},"PeriodicalIF":50.0000,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Influenza vaccine strain selection with an AI-based evolutionary and antigenicity model\",\"authors\":\"Wenxian Shi, Jeremy Wohlwend, Menghua Wu, Regina Barzilay\",\"doi\":\"10.1038/s41591-025-03917-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Current vaccines provide limited protection against rapidly evolving viruses. For example, Centers for Disease Control and Prevention estimates show that the overall influenza vaccine effectiveness against outpatient illness in the United States averaged below 40% between 2012 and 2021. Moreover, the clinical outcomes of a vaccine can be assessed only retrospectively. Here we propose an in silico method named VaxSeer that predicts the antigenic match of vaccine candidates with circulating viruses, in the context of the viruses’ relative dominance in the future influenza season. Based on 10 years of retrospective evaluation using sequencing and antigenicity data, our approach consistently selects strains with better empirical antigenic matches to circulating viruses than annual recommendations. Finally, our predicted estimate of antigenic match exhibits a strong correlation with influenza vaccine effectiveness and reduction in disease burden, highlighting the promise of this framework to drive the vaccine selection process.</p>\",\"PeriodicalId\":19037,\"journal\":{\"name\":\"Nature Medicine\",\"volume\":\"10 1\",\"pages\":\"\"},\"PeriodicalIF\":50.0000,\"publicationDate\":\"2025-08-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41591-025-03917-y\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41591-025-03917-y","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目前的疫苗对快速进化的病毒提供有限的保护。例如,疾病控制和预防中心的估计显示,2012年至2021年期间,美国流感疫苗对门诊疾病的总体有效性平均低于40%。此外,疫苗的临床结果只能回顾性评估。在此,我们提出了一种名为VaxSeer的计算机方法,在病毒在未来流感季节相对占主导地位的背景下,预测候选疫苗与流行病毒的抗原匹配。基于10年的回顾性评估,使用测序和抗原性数据,我们的方法始终选择与流行病毒具有更好的经验抗原匹配的菌株,而不是每年推荐的菌株。最后,我们预测的抗原匹配估计与流感疫苗的有效性和疾病负担的减少有很强的相关性,突出了该框架在推动疫苗选择过程中的前景。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Influenza vaccine strain selection with an AI-based evolutionary and antigenicity model

Influenza vaccine strain selection with an AI-based evolutionary and antigenicity model

Current vaccines provide limited protection against rapidly evolving viruses. For example, Centers for Disease Control and Prevention estimates show that the overall influenza vaccine effectiveness against outpatient illness in the United States averaged below 40% between 2012 and 2021. Moreover, the clinical outcomes of a vaccine can be assessed only retrospectively. Here we propose an in silico method named VaxSeer that predicts the antigenic match of vaccine candidates with circulating viruses, in the context of the viruses’ relative dominance in the future influenza season. Based on 10 years of retrospective evaluation using sequencing and antigenicity data, our approach consistently selects strains with better empirical antigenic matches to circulating viruses than annual recommendations. Finally, our predicted estimate of antigenic match exhibits a strong correlation with influenza vaccine effectiveness and reduction in disease burden, highlighting the promise of this framework to drive the vaccine selection process.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Nature Medicine
Nature Medicine 医学-生化与分子生物学
CiteScore
100.90
自引率
0.70%
发文量
525
审稿时长
1 months
期刊介绍: Nature Medicine is a monthly journal publishing original peer-reviewed research in all areas of medicine. The publication focuses on originality, timeliness, interdisciplinary interest, and the impact on improving human health. In addition to research articles, Nature Medicine also publishes commissioned content such as News, Reviews, and Perspectives. This content aims to provide context for the latest advances in translational and clinical research, reaching a wide audience of M.D. and Ph.D. readers. All editorial decisions for the journal are made by a team of full-time professional editors. Nature Medicine consider all types of clinical research, including: -Case-reports and small case series -Clinical trials, whether phase 1, 2, 3 or 4 -Observational studies -Meta-analyses -Biomarker studies -Public and global health studies Nature Medicine is also committed to facilitating communication between translational and clinical researchers. As such, we consider “hybrid” studies with preclinical and translational findings reported alongside data from clinical studies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信